◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › A › ASMB

Assembly Biosciences Inc (ASMB) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-26

Assembly Biosciences Inc (ASMB) operates in the BIOTECHNOLOGY industry and is headquartered in South San Francisco, United States with about 73 employees. Its market capitalization is roughly $410 million. In the fiscal year ended 2025-12-31, ASMB reported $72M in revenue and ($6M) in net income.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide.

Interactive charts & full statements → Open the ASMB valuation workbench →

ASMB Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Revenue	$75M	$72M	$29M	$7M	$0M	$6M	$79M	$16M	$15M	$9M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—
Gross Profit	$58M	$72M	($27M)	($42M)	$0M	$6M	($22M)	$16M	($58M)	($35M)	$0M	$0M	($24M)	$0M	$0M	$0M	—	—	—
Gross Margin %	77.7%	99.8%	-96.1%	-582.7%	—	100.0%	-28.1%	100.0%	-391.4%	-390.4%	—	—	—	—	—	—	—	—	—
Operating Income (EBIT)	($9M)	($12M)	($45M)	($65M)	($94M)	($133M)	($65M)	($103M)	($93M)	($52M)	($45M)	($30M)	($24M)	($20M)	($25M)	($34M)	($5M)	($3M)	($7M)
Operating Margin %	-11.8%	-16.8%	-159.3%	-902.5%	—	-2121.7%	-81.9%	-643.4%	-626.4%	-579.1%	—	—	—	—	—	—	—	—	—
Net Income	$0M	($6M)	($40M)	($61M)	($92M)	($130M)	($62M)	($98M)	($91M)	($43M)	($44M)	($28M)	($24M)	($19M)	($25M)	($34M)	($15M)	($5M)	($9M)
Net Margin %	-0.1%	-8.5%	-140.9%	-854.8%	—	-2076.3%	-78.6%	-611.6%	-613.0%	-474.7%	—	—	—	—	—	—	—	—	—
EBITDA	$0M	($6M)	($40M)	($61M)	($94M)	($91M)	($58M)	($102M)	($93M)	($52M)	($45M)	($30M)	($24M)	($19M)	($25M)	($47M)	($13M)	($3M)	($7M)
Earnings Per Share (EPS)	$0.03	$-0.55	$-6.69	$-13.38	$-22.82	$-36.00	$-15.66	$-27.83	$-39.80	$-24.12	$-25.69	$-18.12	$-33.99	$-50.03	$-97.40	$-178.62	$-123.33	$-51.00	$-104.17
Shares Outstanding (M)	19M	11M	6M	5M	4M	4M	4M	4M	2M	2M	2M	2M	1M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASMB Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$13M	$8M	$42M	$11M	$10M	$9M	$7M	$7M
Gross Profit	$13M	$8M	$42M	($6M)	($6M)	($5M)	($7M)	($7M)
Gross Margin %	99.9%	99.7%	99.9%	-53.7%	-67.5%	-57.7%	-94.1%	-97.4%
Operating Income (EBIT)	($6M)	($11M)	$20M	($11M)	($11M)	($10M)	($12M)	($11M)
Operating Margin %	-47.4%	-138.4%	46.6%	-100.9%	-115.2%	-105.5%	-156.8%	-160.1%
Net Income	($4M)	($9M)	$22M	($9M)	($10M)	($9M)	($10M)	($10M)
Net Margin %	-28.8%	-110.5%	52.0%	-85.2%	-105.9%	-93.6%	-140.5%	-140.4%
EBITDA	($4M)	($9M)	$22M	($9M)	($10M)	($9M)	($10M)	($10M)
Earnings Per Share (EPS)	$-0.20	$-0.54	$1.97	$-1.20	$-1.33	$-1.17	$-1.57	$-1.51
Shares Outstanding (M)	19M	17M	11M	8M	8M	8M	7M	6M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASMB Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Cash from Operations (CFO)	($38M)	($41M)	($51M)	$23M	($84M)	($93M)	($63M)	($84M)	($65M)	$2M	($35M)	($19M)	($15M)	($18M)	($21M)	($25M)	($5M)	($3M)	($4M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$3M	$2M	$2M	$0M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($39M)	($41M)	($51M)	$22M	($85M)	($96M)	($65M)	($86M)	($65M)	$1M	($35M)	($19M)	($15M)	($18M)	($21M)	($25M)	($5M)	($3M)	($4M)
FCF Margin %	-51.5%	-56.9%	-179.3%	313.9%	—	-1542.9%	-82.4%	-536.4%	-441.1%	11.0%	—	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASMB Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($15M)	($22M)	$14M	($15M)	($17M)	($23M)	$0M	($15M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($15M)	($22M)	$14M	($15M)	($17M)	($23M)	$0M	($15M)
FCF Margin %	-115.8%	-269.3%	33.5%	-140.7%	-174.1%	-248.9%	-5.5%	-222.7%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ASMB Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Assets	$331M	$258M	$119M	$137M	$102M	$191M	$283M	$348M	$268M	$169M	$98M	$134M	$71M	$27M	$21M	$37M	$15M	$0M	$1M
Cash & Cash Equivalents	$32M	$58M	$38M	$20M	$52M	$46M	$59M	$47M	$41M	$82M	$29M	$27M	$29M	$27M	$20M	$37M	$15M	$0M	$0M
Total Liabilities	$25M	$51M	$86M	$96M	$19M	$22M	$43M	$75M	$57M	$56M	$18M	$15M	$13M	$3M	$3M	$3M	$3M	$14M	$10M
Total Debt (Short + Long-Term)	$1M	$1M	$0M	$1M	$3M	$3M	$3M	$3M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$2M	$9M	$6M
Total Shareholders' Equity	$306M	$207M	$33M	$41M	$83M	$169M	$241M	$273M	$211M	$113M	$80M	$119M	$59M	$24M	$18M	$35M	$12M	($13M)	($9M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ASMB viewer.

Other Companies in BIOTECHNOLOGY

PRTA · Prothena Corporation plc — $435 million
CRMD · CorMedix Inc — $433 million
PROK · ProKidney Corp. — $427 million
CCCC · C4 Therapeutics Inc — $415 million
ALLO · Allogene Therapeutics Inc — $408 million
ALT · Altimmune Inc — $397 million
ZURA · Zura Bio Limited Class A Ordinary Shares — $389 million
TECX · Tectonic Therapeutic, Inc. — $387 million

← ASM All “A” companies ASME →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.